



STATE OF WASHINGTON
WASHINGTON STATE BOARD OF HEALTH
1102 SE Quince Street • PO Box 47990
Olympia, Washington 98504-7990

FINAL AGENDA

NOTICE OF PUBLIC MEETINGS

GENETICS TASK FORCE MEETING **Friday, April 12, 2002** **9:15 a.m. – 5:00 p.m.**

Walker Ames Room
Kane Hall
University Of Washington
Seattle, Washington

EMERGENCY MESSAGE PHONE DURING THE MEETING: (360) 561-9488

Please visit our website at
**[http://www.doh.wa.gov/sboh/Priorities/genetics/
genetics.htm](http://www.doh.wa.gov/sboh/Priorities/genetics/genetics.htm)**

****PLEASE NOTE:** Times below are estimates only. The Task Force reserves the right to alter the order of the agenda. For more information regarding testimony, handouts, other questions or for people needing special accommodation, please contact Desiree Robinson at (360) 236-4110 by April 2, 2002.

FINAL AGENDA

- 9:00 a.m.** **Call to Order**
- 1. Approve February 25, 2002 Meeting Minutes- Adoption**
 - 2. Announcements:**
 - 1. Passage of Senate Bill 5207*
 - 2. Proposed changes to HIPAA Privacy Regulations*
- 9:30 a.m.** **3. Future Directions of Academic and Basic Science Research in Human Genetics**
- *Ken Thummel, Ph.D., Department of Pharmaceutics, University of Washington*
- 1) What are the concerns and perceived barriers of academic and basic science researchers with respect to access to and use of DNA and genetic information? 2) What are the future directions and development plans for academic and basic science research? 3) What are appropriate and reasonable incentives to stimulate genetics research and development? 4) What are the research priorities for academic and basic science researchers with respect to product development? How can those products contribute to public health, safety and welfare?*
- 10:30 a.m.** **4. Future Directions of Genomics in Public Health Practice**
- *Maxine Hayes, M.D., M.P.H., State Health Officer, Washington Department of Health*
 - *Karen Edwards, Ph.D., Director, University of Washington Center for Genomics and Public Health*
 - *Amy Klein, M.P.H., ASTHO Director of Genetics*
- 1) What are the concerns and perceived barriers of public health researchers with respect to access to and use of DNA and genetic information? 2) What are the future directions and development plans for public health research? 3) What are appropriate and reasonable incentives to stimulate genetics research and development? 4) What are the research priorities for public health researchers with respect to product development? How can those products contribute to public health, safety and welfare? 5) How is DNA currently used in public health practice and what are the anticipated future uses?*
- 11:30 a.m.** **5. Lunch and Tours of the Henry Art Gallery Gene(sis) Exhibit**
- *Lunch Group One 11:45 to 12:30*
 - *Gallery Tour Group One 11:45 to 12:30*
 - *Lunch Group Two 12:30 to 1:15*
 - *Gallery Tour Group Two 12:30 to 1:15*

FINAL AGENDA

- 1:30 p.m. 6. Private Ventures in Genomic Diagnostic and Treatment Technologies**
- *Eric Earling, Director of Public and Government Affairs, Washington Biotechnology and Biomedical Association*
 - *Steve Gilbert, Director of the Institute of Neurotoxicology and Neurological Disorders*

1) What are the concerns and perceived barriers of biotechnology industry researchers with respect to access to and use of DNA and genetic information? 2) What are the future directions and development plans for the biotechnology industry in WA? 3) What are appropriate and reasonable incentives to stimulate genetics research and product development? 4) What are the research priorities for biotechnology researchers with respect to product development? How can those products contribute to public health, safety and welfare? 5) How do DNA technologies developed by the biotechnology industry currently contribute to public health and what are the anticipated future uses?

- 2:30 p.m. 7. Public Testimony**

Is there public comment on options to address any privacy or discrimination problems identified?

- 3:00 p.m. 15-Minute Break**

- 3:15 p.m. 8. Discussion of Working Glossary, Matrix and Meeting Summary**

- 3:45 p.m. 9. Review of Outline for Final Report and Initial Discussion of Possible Genetics Task Force Conclusions**

What conclusions can be drawn from previous presentations and discussions? What information, conclusions, and recommendations will the final report to the state legislature contain?

- 5:00 p.m. 10. Adjournment**